vs

Side-by-side financial comparison of Flux Power Holdings, Inc. (FLUX) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

STANDARD BIOTOOLS INC. is the larger business by last-quarter revenue ($19.6M vs $14.1M, roughly 1.4× Flux Power Holdings, Inc.). Flux Power Holdings, Inc. runs the higher net margin — 4.3% vs -177.4%, a 181.7% gap on every dollar of revenue. On growth, STANDARD BIOTOOLS INC. posted the faster year-over-year revenue change (-11.5% vs -16.1%). Flux Power Holdings, Inc. produced more free cash flow last quarter ($-5.3M vs $-23.1M). Over the past eight quarters, Flux Power Holdings, Inc.'s revenue compounded faster (-1.2% CAGR vs -12.2%).

Adrian Flux is a British insurance broker that has its head office at East Winch Hall in King's Lynn, Norfolk. The company has become the country’s largest specialist motor insurance brokers and employs around 1,850 staff.

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

FLUX vs LAB — Head-to-Head

Bigger by revenue
LAB
LAB
1.4× larger
LAB
$19.6M
$14.1M
FLUX
Growing faster (revenue YoY)
LAB
LAB
+4.6% gap
LAB
-11.5%
-16.1%
FLUX
Higher net margin
FLUX
FLUX
181.7% more per $
FLUX
4.3%
-177.4%
LAB
More free cash flow
FLUX
FLUX
$17.8M more FCF
FLUX
$-5.3M
$-23.1M
LAB
Faster 2-yr revenue CAGR
FLUX
FLUX
Annualised
FLUX
-1.2%
-12.2%
LAB

Income Statement — Q2 FY2026 vs Q3 FY2025

Metric
FLUX
FLUX
LAB
LAB
Revenue
$14.1M
$19.6M
Net Profit
$601.0K
$-34.7M
Gross Margin
34.7%
48.5%
Operating Margin
5.6%
-168.5%
Net Margin
4.3%
-177.4%
Revenue YoY
-16.1%
-11.5%
Net Profit YoY
131.8%
-28.8%
EPS (diluted)
$0.03
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FLUX
FLUX
LAB
LAB
Q4 25
$14.1M
Q3 25
$13.2M
$19.6M
Q2 25
$16.7M
$21.8M
Q1 25
$16.7M
$40.8M
Q4 24
$16.8M
Q3 24
$16.1M
$22.1M
Q2 24
$13.4M
$22.5M
Q1 24
$14.5M
$45.5M
Net Profit
FLUX
FLUX
LAB
LAB
Q4 25
$601.0K
Q3 25
$-2.6M
$-34.7M
Q2 25
$-1.2M
$-33.5M
Q1 25
$-1.9M
$-26.0M
Q4 24
$-1.9M
Q3 24
$-1.7M
$-26.9M
Q2 24
$-2.2M
$-45.7M
Q1 24
$-3.0M
$-32.2M
Gross Margin
FLUX
FLUX
LAB
LAB
Q4 25
34.7%
Q3 25
28.6%
48.5%
Q2 25
34.5%
48.8%
Q1 25
31.6%
48.4%
Q4 24
32.5%
Q3 24
32.4%
54.9%
Q2 24
26.9%
46.1%
Q1 24
27.8%
53.1%
Operating Margin
FLUX
FLUX
LAB
LAB
Q4 25
5.6%
Q3 25
-16.5%
-168.5%
Q2 25
-4.5%
-118.1%
Q1 25
-9.4%
-80.8%
Q4 24
-8.8%
Q3 24
-7.5%
-120.9%
Q2 24
-13.5%
-134.5%
Q1 24
-17.8%
-132.2%
Net Margin
FLUX
FLUX
LAB
LAB
Q4 25
4.3%
Q3 25
-19.4%
-177.4%
Q2 25
-7.0%
-153.7%
Q1 25
-11.6%
-63.8%
Q4 24
-11.2%
Q3 24
-10.4%
-122.0%
Q2 24
-16.8%
-203.3%
Q1 24
-20.8%
-70.6%
EPS (diluted)
FLUX
FLUX
LAB
LAB
Q4 25
$0.03
Q3 25
$-0.15
$-0.09
Q2 25
$-0.07
$-0.09
Q1 25
$-0.12
$-0.07
Q4 24
$-0.11
Q3 24
$-0.10
$-0.07
Q2 24
$-0.13
$-0.12
Q1 24
$-0.18
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FLUX
FLUX
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$129.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$7.5M
$399.7M
Total Assets
$30.1M
$539.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FLUX
FLUX
LAB
LAB
Q4 25
Q3 25
$1.6M
$129.4M
Q2 25
$1.3M
$158.6M
Q1 25
$505.0K
$150.9M
Q4 24
$883.0K
Q3 24
$559.0K
$210.6M
Q2 24
$643.0K
$269.8M
Q1 24
$1.3M
$287.1M
Total Debt
FLUX
FLUX
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Stockholders' Equity
FLUX
FLUX
LAB
LAB
Q4 25
$7.5M
Q3 25
$-3.3M
$399.7M
Q2 25
$-5.4M
$424.5M
Q1 25
$4.4M
$454.6M
Q4 24
$-2.7M
Q3 24
$-1.1M
$489.3M
Q2 24
$194.0K
$510.3M
Q1 24
$2.1M
$577.3M
Total Assets
FLUX
FLUX
LAB
LAB
Q4 25
$30.1M
Q3 25
$29.7M
$539.6M
Q2 25
$34.8M
$557.0M
Q1 25
$30.6M
$579.6M
Q4 24
$29.0M
Q3 24
$30.6M
$681.5M
Q2 24
$32.3M
$708.7M
Q1 24
$34.0M
$777.7M
Debt / Equity
FLUX
FLUX
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FLUX
FLUX
LAB
LAB
Operating Cash FlowLast quarter
$-5.2M
$-22.2M
Free Cash FlowOCF − Capex
$-5.3M
$-23.1M
FCF MarginFCF / Revenue
-37.4%
-118.1%
Capex IntensityCapex / Revenue
0.9%
4.5%
Cash ConversionOCF / Net Profit
-8.59×
TTM Free Cash FlowTrailing 4 quarters
$-6.3M
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FLUX
FLUX
LAB
LAB
Q4 25
$-5.2M
Q3 25
$889.0K
$-22.2M
Q2 25
$610.0K
$-20.7M
Q1 25
$-1.6M
$-30.3M
Q4 24
$2.8M
Q3 24
$944.0K
$-27.9M
Q2 24
$-4.8M
$-39.0M
Q1 24
$-229.0K
$-62.5M
Free Cash Flow
FLUX
FLUX
LAB
LAB
Q4 25
$-5.3M
Q3 25
$726.0K
$-23.1M
Q2 25
$-43.0K
$-22.6M
Q1 25
$-1.7M
$-35.3M
Q4 24
$2.7M
Q3 24
$746.0K
$-30.1M
Q2 24
$-5.7M
$-41.0M
Q1 24
$-479.0K
$-63.3M
FCF Margin
FLUX
FLUX
LAB
LAB
Q4 25
-37.4%
Q3 25
5.5%
-118.1%
Q2 25
-0.3%
-103.6%
Q1 25
-10.4%
-86.6%
Q4 24
16.1%
Q3 24
4.6%
-136.4%
Q2 24
-42.2%
-182.2%
Q1 24
-3.3%
-138.9%
Capex Intensity
FLUX
FLUX
LAB
LAB
Q4 25
0.9%
Q3 25
1.2%
4.5%
Q2 25
3.9%
8.7%
Q1 25
1.1%
12.4%
Q4 24
0.7%
Q3 24
1.2%
10.2%
Q2 24
6.4%
8.6%
Q1 24
1.7%
1.7%
Cash Conversion
FLUX
FLUX
LAB
LAB
Q4 25
-8.59×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FLUX
FLUX

Segment breakdown not available.

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons